BSI-730 based ADC / Biosion - LARVOL DELTA

BSI-730, a first-in-class HER2xPD-L1 bi-specific ADC, demonstrates potent anti-tumor activity in HER2-low models via selective tumor cell killing and immune modulation (AACR 2026) - "Engaging HER2 and PD-L1 simultaneously enables enhanced internalization, selective tumor cell killing, and promoted anti-tumor immune response via payload-induced immunogenic cell death, subsequently improving efficacy in HER2-low/null patients. The HER2xPD-L1 bi-specific antibody was composed of trastuzumab and the humanized anti-PD-L1 antibody identified from A/J mice immunized with PD-L1-ECD-Fc...The potency of BSI-730 was higher than and comparable to T-Dxd in HER2-low and high expressing cell lines, respectively... BSI-730 is a first-in-class HER2xPD-L1 bi-specific ADC tailored for HER2-low/null patients leveraging dual function of selective cell killing and immune modulation. The current pre-clinical data highlight the potential of BSI-730 in HER2-low setting and further pharmacokinetics, toxicity, and IND-enabling studies are underway."

ADC • Bispecific • IO biomarker • Tumor cell • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Biosion to Present Three Posters at the 2024 AACR Meeting (PRNewswire) - "Biosion...today announced upcoming presentations of pre-clinical data for its oncology pipeline assets, including BSI-111, an anti-CD16a monoclonal antibody, BSI-730, a HER2/PD-L1 bispecific antibody and BSI-093, an anti-BTN3A monoclonal antibody at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 5 to 10, 2024...BSI-111 demonstrates superior biophysical properties and functional characteristics, supporting the development of anti-CD16a-based NK cell engagers for the potential benefit of cancer patients...BSI-730 showed comparable binding affinity to HER2 as compared to trastuzumab, as well as comparable bioactivity to the parental anti-PD-L1 antibody regarding PD-L1 binding and PD-1/PD-L1 blocking....BTN3A's expression is significantly higher in tumor samples of cholangiocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, compared to their counterpart normal tissue controls."

Preclinical • Cholangiocarcinoma • Gastrointestinal Cancer • Head and Neck Cancer • Liver Cancer • Oncology • Squamous Cell Carcinoma of Head and Neck